Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 17/20 | 0.75 |
| ▸ | JAK1 | P23458 | 5/20 | 0.75 |
| ▸ | JAK2 | O60674 | 6/20 | 0.67 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | STAT1 | P42224 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065955 | 1.00 | TYK2 (0.75) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL30065951 | 0.94 | TYK2 (0.76) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL28665049 | 0.92 | TYK2 (0.66) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL31369049 | 0.90 | JAK2 (0.74) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL28665008 | 0.90 | JAK2 (0.74) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL27199357 | 0.89 | TYK2 (0.67) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL30498286 | 0.89 | TYK2 (0.67) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL22313324 | 0.87 | TYK2 (0.77) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL30065989 | 0.87 | TYK2 (0.77) | TYK2JAK1JAK2STAT3STAT1 | |
| SCHEMBL16712842 | 0.86 | TYK2 (1.00) | TYK2JAK1JAK2STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| CN-115448910-B | Pyridazine derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-117263918-A | Pyridazine derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-111757878-B | Pyridazine derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| CN-115448910-A | Pyridazine derivative inhibitor, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-111757878-A | Pyridazine derivative inhibitor, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2020156311-A1 | PYRIDAZINE DERIVATIVE INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2020-08-06 | — | — | WO | disclosed |
| WO-2020156311-A1 | PYRIDAZINE DERIVATIVE INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.